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Variations in Dysbindin-1 are associated with
cognitive response to antipsychotic drug treatment
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Antipsychotics are the most widely used medications for the treatment of schizophrenia
spectrum disorders. While such drugs generally ameliorate positive symptoms, clinical
responses are highly variable in terms of negative symptoms and cognitive impairments.
However, predictors of individual responses have been elusive. Here, we report a pharma-
cogenetic interaction related to a core cognitive dysfunction in patients with schizophrenia.
We show that genetic variations reducing dysbindin-1 expression can identify individuals
whose executive functions respond better to antipsychotic drugs, both in humans and in
mice. Multilevel ex vivo and in vivo analyses in postmortem human brains and genetically
modiﬁed mice demonstrate that such interaction between antipsychotics and dysbindin-1 is
mediated by an imbalance between the short and long isoforms of dopamine D2 receptors,
leading to enhanced presynaptic D2 function within the prefrontal cortex. These ﬁndings
reveal one of the pharmacodynamic mechanisms underlying individual cognitive response to
treatment in patients with schizophrenia, suggesting a potential approach for improving the
use of antipsychotic drugs.
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Antipsychotics are the ﬁrst-line and most widely usedmedications for the management of schizophrenia spec-trum and other psychotic disorders1. In agreement with
the heterogeneous nature of these disorders, clinical responses to
antipsychotics drugs are highly variable2. Thus, clinical guidelines
strongly recommend adapting antipsychotic treatments to each
individual case1. However, to date, only very scarce biomarkers
exist to implement more effective and personalized healthcare.
Efforts have been made to improve the assessment and deﬁ-
nition of treatment-resistant schizophrenia. However, the iden-
tiﬁcation of criteria for schizophrenia cognitive deﬁcits is still
incomplete, in part because of the lack of cognitive symptom
domains in the most widely used clinical rating scales (e.g., the
PANSS, BPRS, SANS, and SAPS)3. Nonetheless, the consensus is
that clinical responses for negative symptoms and cognitive
impairments are suboptimal and highly variable. Notably, cog-
nitive deﬁcits are considered one of the main sources of disability,
having the most critical impact on public health and long-term
outcomes4,5. Treatments with ﬁrst- and second-generation anti-
psychotics produce small neurocognitive improvements in both
chronic and ﬁrst-episode schizophrenia patients6–10. Never-
theless, cognitive responses to antipsychotic drugs show marked
interindividual variability11,12, and the mechanistic basis of this
seemingly unpredictable variability is unknown.
All antipsychotic drugs interact with dopamine D2 receptors13,
with variable ranges of D2 occupacy suggested to be important
for optimal clinical and cognitive responses13–15. From a phar-
macokinetic perspective, genetic variations such as those in
CYP2D6, CYP3A4/5, and ABCB1 might impact the metabolism
and distribution of antipsychotic drugs, potentially affecting the
margin between the dosages that are required for efﬁcacy and
those associated with side effects16,17. Shifting to a pharmaco-
dynamic perspective, genetic variations inﬂuencing D2 receptors
could in principle also inﬂuence the efﬁcacy of antipsychotic
drugs13. Genetic variations in the dystrobrevin binding protein 1
(DTNBP1) gene, encoding dysbindin-118–20 (Dys), a synaptic
protein regulating synaptic vesicles and receptors recycling21,22,
can alter D2 receptor availability. Moreover, genetic variations in
Dys might interfere with the dopaminergic system, altering cog-
nitive functions in both mice and healthy humans19,20,23–25.
Dystrophin and its binding partners (such as Dys) have been
implicated in schizophrenia by recent copy number variant
(CNV) studies26, by older linkage studies27–32, and by post-
mortem human brain expression data33,34. However, GWAS have
challenged this association35. Other ﬁelds such as cancer geno-
mics and cardiovascular medicine have suggested that genetic
variants predicting drug responses might be unrelated to the
cause of the target pathology36. Based on the physiological impact
of Dys on D2 receptors, we hypothesize in this work that varia-
tion in the Dys gene may be related to variation in cognitive
response to antipsychotic drugs.
Through a translational mouse-human approach, we studied
the effects of common functional genetic variations resulting in
reduced Dys expression on cognitive responses to antipsychotic
drugs. We show that genetic variations associated with reduced
Dys expression in the human brain differentiate individuals
whose executive functions respond better to these drugs.
Mechanistically, using lentiviral-vector-mediated microRNA
(miR) silencing and neurochemical strategies for region-speciﬁc
investigation in mice and postmortem human brain gene
expression analyses, we demonstrate that this interaction between
antipsychotics and Dys relies selectively on the function of
dopamine D2 receptors within the prefrontal cortex (PFC). In
particular, Dys genetic reduction is associated with an
antipsychotic-dependent increase in the ratio between the
D2Short (D2S) and D2Long (D2L) isoforms in the PFC of both
humans and mice, which results in a potentiation of cortical
presynaptic D2 signaling. A genetic approach in mice demon-
strates that the D2S/D2L imbalance in favor of D2S is the cause of
the cognitive improvements that occur in response to anti-
psychotic administration in the context of reduced Dys. Certainly,
Dys is not expected to be the only relevant molecular probe
involved in responses to antipsychotic drugs. Nevertheless, our
ﬁndings provide another step toward personalized treatment37,38
for schizophrenia, suggesting Dys-related mechanisms as a tool
for a more focused approach to alleviating cognitive disabilities
based on a deﬁned biological mechanism that moderates the
response to antipsychotics treatment.
Results
Dys-antipsychotics interaction in human executive functions.
We ﬁrst investigated whether functional Dys genetic variants
would differentiate cognitive abilities in patients with
schizophrenia undergoing chronic antipsychotic drug treatment.
We used a three-marker (rs2619538-rs3213207-rs1047631)
haplotype at the DTNBP1 gene locus (Dys Hap) previously
associated with a pattern of cognitive-related PFC functional
activation consistent with reduced Dys in mouse models19. RNA
sequencing from the dorsolateral PFC (DLPFC) of 594 human
subjects demonstrated that carriers of the Dys Hap (T-A-A),
hereinafter referred to as Dys Hap+/− and −/− (demographic
details in Supplementary Table 1 and genotype frequencies in
Supplementary Table 2), had reduced Dys expression (Fig. 1a)
compared to Dys Hap+/+ individuals. We recruited 259 patients
receiving chronic treatment with antipsychotic medication, and
we assessed their executive function abilities, as these are cogni-
tive hallmarks of schizophrenia39. Notably, executive function
deﬁcits in patients with schizophrenia are particularly evident in
extradimensional set shifting (EDS) and in the analogous category
shift of the Wisconsin Card Sorting Task (WCST)40,41. We found
that Dys Hap+/− and −/− patients, with putatively reduced
expression of Dys, performed better than Dys Hap+/+ patients
(Fig. 1b–d). In particular, Dys Hap−/− patients made fewer
perseverative (Fig. 1b) and non-perseverative errors (Fig. 1c) and
completed more WCST categories (Fig. 1d) than Dys Hap+/+
patients did. Similarly, Dys Hap+/− patients made fewer
non-perseverative errors than Dys Hap+/+ patients did. No
Dys Hap-dependent differences were present in demographic
characteristics, PANSS scores, or the duration or dosage of cur-
rent antipsychotic treatments (Supplementary Table 1). All SNPs
were in Hardy–Weinberg equilibrium (HWE; Supplementary
Table 2).
To check for replicability in an independent cohort of
subjects, we next investigated this association using the
neurocognitive battery used in the Clinical Antipsychotic
Trials of Intervention Effectiveness (CATIE), a double-blind
multicenter trial sponsored by the National Institute of Mental
Health (NIMH) to assess responses to antipsychotic drugs.
Each patient was randomly assigned to treatment with a
single antipsychotic drug, and any previous therapy was
discontinued during the ﬁrst 2 weeks of double-blind treatment.
After a baseline assessment, patients were followed for up to
18 months. We used a sample of 359 patients who completed the
study and for whom genetic data were available. We found that
Dys Hap−/− and+/− patients, characterized by reduced Dys
expression, displayed a better WCST performance compared to
Dys Hap+/+ patients (Fig. 1e and Supplementary Table 3). Thus,
the CATIE study conﬁrmed that genetic variations associated
with reduced Dys are associated with better executive function
response to antipsychotic treatment in patients with
schizophrenia.
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Antipsychotics improves cognition based on Dys genetics. To
reduce the possibility that multidrug treatments and the long
duration of the illness could have confounded the results, we
recruited another independent cohort of patients with schizo-
phrenia in their ﬁrst episode of psychosis. These patients were
naive to medication when recruited and were treated for the ﬁrst
time with one antipsychotic (risperidone or aripiprazole) for
4 weeks, then evaluated with the WCST. Similar to chronic
patients, ﬁrst-episode patients with the Dys Hap−/− genotype
had better attentional set-shifting abilities than non-carriers (Dys
Hap+/+) (Fig. 2a–c).
Ideally, it would have been interesting to have an untreated or
placebo group of patients with schizophrenia never treated with
antipsychotics. However, to recruit a sufﬁcient number of these
subjects for further genetic stratiﬁcation would be challenging
and would involve a number of ethical issues. Thus, we used mice
to test the possibility that genetic variations selectively reducing
Dys expression would confer executive function beneﬁts follow-
ing administration of antipsychotics. We tested mice with
reduced levels of dysbindin-1 (Dys+/−) and control littermates
(Dys+/+) using the Intra-/Extra-Dimensional Attentional Set-
Shifting task (ID/ED Operon task)42, which is equivalent to the
human WCST. Starting from 2 weeks before the test, mice were
treated with risperidone, a commonly used antipsychotic, or with
vehicle. Chronic treatment with risperidone not only rescued the
attentional set-shifting impairment of Dys+/− mice but also
improved their EDS performance compared to that of vehicle-
and risperidone-treated Dys+/+ mice (Fig. 2d–f and Supple-
mentary Fig. 1a–c). Risperidone treatment had no effect on Dys
+/+ mice (Fig. 2d–f and Supplementary Fig. 1a–c). We further
tested whether any residual effect of injections and manipulations
might have existed. Non-manipulated mice with genetically
reduced Dys showed a selective deﬁcit in EDS abilities compared
to control wild-type littermates (Fig. 3a–c and Supplementary
Fig. 2a–c). Furthermore, as predicted by these mouse data,
healthy Dys Hap−/− humans (demographic characteristics in
Supplementary Table 1) showed a cognitive disadvantage in
attentional set shifting on the WCST compared to matched
healthy Dys Hap+/+ subjects (Fig. 3d–f). These results support
the conclusion that genetic variations reducing Dys may improve
the responsiveness of executive function to treatments with
antipsychotic drugs.
Cortical D2 are necessary for Dys-antipsychotics effects. The
mechanistic basis of the unpredictable variability in clinical
responses to antipsychotics is still largely unexplored. Prompted
by the behavioral effects, we sought to identify a mechanism for
this pharmacogenetic interaction. We hypothesized that the
antipsychotics-dysbindin-1 interaction might converge on dopa-
mine D2 signaling within the PFC. Indeed, (1) D2 receptors are a
common target of antipsychotic drugs43; (2) cortical D2 recep-
tors, but not D1 receptors, are modulated by Dys genetic varia-
tions18,20; (3) down-regulation of Dys modulates sensitivity to
D2-like agonists20,44; (4) genetic variations of Dys interfere with
the dopaminergic system, leading to altered cognition in both
mice and healthy humans19; (5) as in humans, the selective
alteration in EDS performance in mice points to involvement of
the mPFC45; (6) no genotype, treatment and genotype-by-
treatment effects were evident in Dys, D1, glutamatergic, and
serotoninergic receptors expression in the mPFC (Supplementary
Fig. 3 and Supplementary Table 4). Nevertheless, antipsychotics
target multiple receptors43, and D1 receptor signaling has been
implicated more than D2 in PFC-dependent cognitive func-
tions46. Thus, to assess the selective role of D2 signaling, we
inactivated D2 receptors in Dys+/− mice by bilaterally injecting
into the mPFC a lentivirus delivering a synthetic miR coupled to a
GFP tag. Two weeks later, the virus-injected mice were chroni-
cally treated with risperidone or vehicle and then tested in the ID/
ED task (Fig. 4a). Silencing D2 receptors in the mPFC of Dys+/−
mice was sufﬁcient to eliminate the beneﬁcial effect of risperidone
on attentional set-shifting abilities (Fig. 4b, c and Supplementary
Fig. 4). This demonstrates that the dysbindin-antipsychotic
interaction depends on D2 functioning in the mPFC.
Antipsychotic-Dys interaction potentiates presynaptic D2. We
then examined the effect of antipsychotic treatment on cortical
D2 signaling in subjects with reduced levels of Dys. In mice, Dys
reduction, risperidone treatment and their interaction all failed to
affect the expression of D2 (Fig. 5a) in the mPFC. However,
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Fig. 1 Genetic variations reducing dysbindin-1 are associated with better executive functions in antipsychotic-treated subjects. a Reduction of dysbindin-1
expression in the DLPFC of Dys Hap+/− and −/− human subjects (light and dark blue circles, respectively) compared to Dys Hap+/+ (white circles)
(n= 594; one-way ANOVA, F(2, 591)= 5.70, p < 0.005). Analysis with the R package haplo.stats v1.7.7 yielded a global p value of 3.5 × 10−7 for DTNBP1 at
the gene level, which was in part driven by the speciﬁc Dys haplotype (p= 2.54 × 10−5), associated with lower expression (i.e., Dys Hap+/+ > Dys Hap
+/− > Dys Hap−/−). b–d Patients with schizophrenia with reduced dysbindin-1 expression (Dys Hap−/−) made b fewer perseverative (n= 259; one-
way ANOVA, F(2, 251)= 4.64, p < 0.01), and c fewer non-perseverative errors (one-way ANOVA, F(2, 251)= 4.21, p < 0.01) on the WCST, and d passed more
categories (one-way ANOVA, F(2, 251)= 4.74, p < 0.01). No Dys-haplotype-dependent differences were present in demographical characteristics or in the
duration or dosage of antipsychotic treatments (see Supplementary Table 1). All single-nucleotide polymorphisms (SNPs) were in Hardy–Weinberg
equilibrium (HWE) for healthy subjects and patients with schizophrenia (see Supplementary Table 2). e Patients with schizophrenia with reduced
dysbindin-1 (Dys Hap+/− and −/−, blue circles), who were enrolled in the NIH CATIE trial showed better WCST performance than those with the Dys
Hap+/+ (white circles) genotype. The WCST score was calculated by averaging z-scores for preservative errors and categories achieved (n= 359; two-
way ANOVA, time effect, F(3, 1046)= 5.03, p < 0.005; genotype effect, F(1, 1046)= 4.38, p < 0.04). Error bars represent S.E.M. *p < 0.05, **p < 0.005
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because D2 receptors exist in two different splicing isoforms47, we
also assessed whether the dysbindin-antipsychotics interaction
might differently impact the D2L and D2S isoforms. Chronic
treatment with risperidone increased the D2S/D2L ratio in the
mPFC of Dys+/− but not Dys+/+ mice (Fig. 5b). To investigate
whether a similar effect could be observed in the human brain, we
analyzed the gene expression of D2 receptor isoforms in a sample
(n= 101) of DLPFC tissue from patients with schizophrenia. As
in mice, we found that the D2S/D2L ratio was increased in Dys
Hap−/− patients if and only if antipsychotic treatments could be
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mice (n= 7, dark blue bar) needed (a) more trials (one-way ANOVA,
genotype effect, F(1, 15)= 7.69, p < 0.05) and (b) more time than +/+ mice
(one-way ANOVA, genotype effect, F(1, 15)= 7.69, p < 0.05) to complete
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to respond during the EDS in Dys+/− mice (one-way ANOVA, genotype
effect, F(1, 30)= 8.43, p < 0.05). d, e Dys Hap+/− and −/− healthy
volunteers (light and dark blue bar, respectively) made (d) similar
perseverative errors (one-way ANOVA, F(2, 311)= 1.64, p= 0.19; n= 314)
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Fig. 2 Antipsychotic drug treatment improves executive functions
selectively in subjects with reduced dysbindin-1 expression. a–c Among
patients with schizophrenia after their ﬁrst episode of psychosis, those with
reduced dysbindin-1 expression (Dys Hap−/−, blue dark bar) made a less
perseverative errors (one-way ANOVA, F(2, 34)= 3.59, p < 0.05; n= 45),
b non-perseverative errors (one-way ANOVA, F(2, 34)= 3.59, p < 0.05) and
c passed more categories (one-way ANOVA, F(2, 34)= 3.15, p= 0.05) on
the WCST than those with Dys Hap+/+ (white bar). d, e Dys+/− mice
(dark blue bar) after risperidone treatment (Ris in red) required d fewer
trials (two-way ANOVA, genotype × treatment, F(1, 24)= 13.40, p < 0.005,
n= 7 per group) and e less time (two-way ANOVA, genotype × treatment,
F(1, 24)= 5.69, p < 0.05) than Dys+/+ (white bar) to complete the EDS of
the ID/ED task. f Dys+/− mice (dark blue bar) needed more time to make
a response (latency to respond) in the EDS than vehicle-treated (white bar)
wild-type controls needed (t= 2.54, df= 15.60, p < 0.05). However, we did
not ﬁnd a treatment effect (two-way ANOVA, genotype × treatment, F(1,
20)= 1.56, p= 0.20). Error bars represent S.E.M. *p < 0.05
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detected after postmortem analysis (Fig. 5c). The expression of
D2 receptor isoforms was not altered by the Dys Hap in
medication-naive healthy subjects (n= 199; Fig. 5d). Thus, we
uncovered an interaction between antipsychotic drug treatments
and Dys genetic variations in the PFC that alters the expression of
D2 receptor isoforms in favor of D2S.
The D2S isoform is the predominant D2 presynaptic
autoreceptor47,48, providing negative feedback control of dopa-
mine synthesis and release. Moreover, synaptic secretion of
accumulated antipsychotics exerts an autoinhibitory effect on
vesicular exocytosis, affecting neurotransmitter release49. Thus, to
assess the functional and dynamic consequences of
the dysbindin-by-antipsychotics interaction for the cortical
D2S/D2L ratio, we performed in vivo microdialysis in the mPFC
of freely moving Dys+/+ and +/−mice after chronic risperidone
or vehicle treatments (Fig. 6a). Risperidone treatment in
Dys+/− mice restored basal dopamine to wild-type levels while
having no effect in Dys+/+ (Fig. 6b). Notably, infusion of the
D2-preferring agonist quinpirole in the mPFC by reverse dialysis
unraveled a larger reduction of dopamine release in Dys+/− than
in +/+ following risperidone treatment (Fig. 6c), but not in
vehicle-treated mice (Fig. 6d). This enhanced presynaptic D2
response in Dys+/−mice was selectively dependent on the effects
of risperidone on mPFC D2 receptors, as mPFC lentiviral
D2 silencing abolished it (Fig. 6e). These results provide in vivo
evidence supporting the increased D2S/D2L ratio and demon-
strate that risperidone treatment enhanced cortical presynaptic
D2 functioning exclusively when Dys was reduced. These results
add important insights into previous evidence showing that
potentiation of D2 pathways in the PFC of humans, monkeys,
and rodents might facilitate executive functions50–52.
Increased D2S/D2L ratio in Dys improves executive functions.
To demonstrate selectively that a D2S/D2L imbalance in favor of
D2S is causally linked to the improved executive functions found
in the context of reduced Dys, we backcrossed Dys+/− mutants
with D2L+/− mice (Fig. 7a). D2L+/− mice have genetically
reduced expression of the D2L isoform and upregulation of
D2S47. In agreement with this expression pattern, we conﬁrmed
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6–7 each group). b Increased D2S/D2L ratio in the mPFC of Dys+/− after chronic treatment with Ris (n= 6–7 each group; two-way ANOVA, treatment,
F(1, 25)= 8.67, p < 0.05; genotype, F(1, 25)= 4.25, p < 0.05). c The D2S/D2L ratio in the DLPFC was increased in schizophrenia patients with reduced
dysbindin-1 expression (Dys Hap −/−, dark blue circles) who tested positive in antipsychotic screening (ADP pos.) compared to Dys Hap+/+ patients
(white circles; one-way ANOVA, F(2, 98)= 3.26, p < 0.05; n= 101). We did not observe any difference in D2S/D2L ratio from postmortem human brains of
the DLPFC of patients with schizophrenia in which antipsychotics where not detected (one-way ANOVA, F(2, 55)= 0.90, p= 0.41; n= 58). d The D2S/D2L
ratio in the DLPFC from postmortem human brains of healthy subjects was similar across genotypes (n= 199; one-way ANOVA, F(2, 194)= 1.06, p= 0.34).
Error bars represent S.E.M. *p < 0.05
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an imbalance of the D2 isoforms towards elevated expression of
D2S in the PFC of both D2L+/−mutant and Dys+/− ×D2L+/−
double mutant mice (Fig. 7b). We then tested the executive
functions of wild-type, Dys+/−, D2L+/−, and double
Dys+/−D2L+/− littermates in the ID/ED Operon task. Double
Dys+/−D2L+/− mutant mice outperformed wild-type controls
and Dys+/− animals exclusively in the EDS stage (Fig. 7c, d). By
contrast, D2L+/− single mutants showed the same EDS perfor-
mance as wild-type littermates (Fig. 7c, d). These ﬁndings
demonstrate that the imbalanced D2S/D2L ratio produced by
chronic treatment with antipsychotics in mice with a genetic
reduction of Dys leads to improvements in attentional set
shifting.
Discussion
The main ﬁnding of this study is that genetic variations associated
with reduced Dys expression provide a background for a more
favorable cognitive executive functions response to antipsychotic
drugs. We show that this pharmacogenetic interaction mechan-
istically relies on an enhancement of presynaptic cortical dopa-
mine/D2 signaling through an imbalance of the D2S and D2L
isoforms.
The NIMH reports that the cost of treating patients with
schizophrenia in the US is nearly $19 billion a year (one-fourth of
all mental health costs). On the European continent, the annual
mean cost per patient is estimated to range from approximately
€7000 to €40,000, depending on the country53. Antipsychotics are
the frontline drugs for the management of schizophrenia and are
effective in treating acute and chronic symptoms of schizo-
phrenia, as well as reducing the risk of psychotic relapses, suicidal
behavior, and hospitalization53,54. However, the percentage of
patients able to integrate in the community and experience stable
remission is only 30%, especially due to cognitive deﬁcits, which
are especially resistant to treatment55. Indeed, the effect of anti-
psychotic medications on cognitive function is less clear, despite
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probe dialyzing portion within the mPFC and timeline of the experiment. Dys+/+ and +/− mice received chronic vehicle or risperidone treatment and,
after 4 weeks, were implanted with a dialysis probe for measurement of basal extracellular dopamine levels and quinpirole-induced dopamine release. b
Increased basal extracellular dopamine levels in the mPFC of Dys+/− are restored by risperidone (two-way ANOVA, genotype × treatment,
F(1, 27)= 4,61, p < 0.05; n= 6–7/group). p= 0.39 vs. Dys+/+. c Quinpirole infusion (gray area) equally decreased extracellular dopamine release in the
mPFC of Dys+/+ (white circles) and+/− (blue circles) mice after chronic treatment with Veh (two-way RM ANOVA, time, F(6, 60)= 2,83; p < 0.05). *p <
0.05 vs. baseline. d Dys+/− (blue circles) mice following chronic treatment with Ris (in red) showed higher efﬁcacy of mPFC quinpirole infusion (gray
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risperidone-treated +/+ mice (white circles; p= 0.38 vs. baseline). **p < 0.005 vs. Dys+/+. e Dys+/− mice received a synthetic microRNA (miR) to
inactivate D2 receptors (LV-miR-D2, green circles) or a control miR (LV-miR-control, purple circles) in the mPFC. After 2 weeks, animals received daily
injections of Veh or Ris for 28 days (to parallel behavioral experiment in Figs. 2, 4) and then have been implanted with a dialysis probe. On the following
day in vivo microdialysis quinpirole-induced dopamine release was measured. In Dys+/− treated with Ris, D2 silencing even increased dopamine release.
Injection of a control miR in Dys+/− Ris-treated mice further conﬁrmed a decrease of quinpirole-mediated dopamine release (two-way RM ANOVA,
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conditions, genetic variations resulting in reduced dysbindin-1 expression increases tonic extracellular dopamine levels (black dots). Long-term
administration of risperidone (red dots) alters the balance between short and long isoforms of D2 receptors, resulting in the potentiation of D2 presynaptic
signaling. Antipsychotic drugs accumulate in synaptic vesicles and are secreted from upon exocytosis49. Moreover, antipsychotic drugs preferentially bind
D2L postsynaptic receptors47, 63, which might cause D2L/D2S imbalance in favor of D2S autoreceptors13
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the fact that cognitive impairments in schizophrenia are strong
predictors of poor function and outcome5,53. Moreover, the
capacity for self-care is related to cognitive performance, and
once hospitalization has occurred, the presence of cognitive
impairment slows the rate of the overall clinical improvement,
lengthening the hospital stay56. Considering the overall highly
heterogeneous population of patients with schizophrenia, it has
been reported that treatment with ﬁrst-generation and second-
generation antipsychotics produces small but consistent neuro-
cognitive improvements6,7. Further investigations have high-
lighted that cognitive functions in patients with chronic
schizophrenia show marked heterogeneity11,12, spanning from
normal to impaired. Many genetic and environmental factors
likely underlie these variable responses to schizophrenia treat-
ments. Our current ﬁndings highlight one of the mechanisms that
could be used to identify a subset of patients with schizophrenia
whose executive functions are likely to respond better to anti-
psychotics, based on Dys mechanisms. This could affect a sig-
niﬁcant number of patients, as the Dys haplotype is a common
genotype (Supplementary Table 2). Ultimately, these results
might be potentially applied to increase the effectiveness of
antipsychotics and reduce the duration of the empirical testing
often required to select appropriate medication or doses of
antipsychotic drugs. Our ﬁndings are in keeping with the idea of
improving the use of existing drugs57, with the ﬁnal goal of
implementing a precision medicine approach37. This study sup-
ports the idea that focusing on the genetics of individual patients
rather than on the overall population is applicable to psychiatric
disorders, analogous to what has been achieved with che-
motherapeutic strategies in cancer genomics.
Our ﬁndings complement previous evidence that points to
genetic variations inﬂuencing pharmacokinetic factors as a source
of variability in the responses to antipsychotic drugs. In parti-
cular, risperidone is transformed primarily by hepatic metabolism
via the cytochrome drug-metabolizing gene CYP2D658 to its
major active metabolite, 9-hydroxyrisperidone or paliperidone.
The CYP2D6 gene is highly polymorphic, resulting in large
individual differences in CYP2D6 enzymatic activity59,60. Simi-
larly, genetic variants in CYP3A, CYP1A2, and the ABCB1
membrane transporter, P-glycoprotein, have also been suggested
to regulate the bioavailability of antipsychotic drugs61. Moreover,
a recent study highlighted an interaction between pharmacoge-
netic factors and antipsychotic inﬂuences on potassium channel
activity as another potential source of individual variation in
response62. A complete assessment of genetically determined
pharmacodynamic and pharmacokinetic mechanisms will pro-
vide a better assessment of the variability in adverse reactions and
clinical responses to antipsychotic drug treatments. Future studies
should consider whether the variability in cognitive responses
that we reported here might differ between the different available
antipsychotic drugs, different doses used and/or the presence of
other add-on drugs (e.g., anxiolytic, antidepressant, and mood-
stabilizing drugs that are commonly used in combination with
antipsychotic drugs). Finally, the newer antipsychotic drugs such
as clozapine target many other neurotransmitter systems that
might also contribute to response variability.
Our data suggest a genetic parsing of variability in cognitive
response to antipsychotic drugs that converges on the basic
pharmacology of these medications. These effects might not be
related to the genetic causes of schizophrenia, as revealed by
current GWAS. This mirrors ﬁndings in oncology and cardio-
vascular medicine36 in which genetic variations predicting ther-
apeutic responses are not always linked to the causes of the
pathology. In particular, we identiﬁed in the increased relative
cortical expression of the D2S isoform a possible mechanism to
explain the better executive-function responses to antipsychotic
drugs in subjects with Dys reduction. Therapeutic responses to
antipsychotic drugs are highly dependent on a strict range of D2
occupacy, with lower or higher binding being potentially detri-
mental to neurocognitive functions13–15. Moreover, it has been
suggested that antipsychotic drugs preferentially bind D2L
receptors47,63. Thus, chronic preferential antagonism of D2L
receptors might shift the D2L/D2S balance toward the D2S iso-
form. The elevated propensity toward this process brought by
reduced Dys might be related to its impact on intracellular traf-
ﬁcking at the synaptic level. Indeed, antipsychotic drugs accu-
mulate in synaptic vesicles and are secreted upon exocytosis49.
Moreover, Dys has an established role in rapid presynaptic
induction of synaptic homeostasis64. Indeed, in vivo activity-
dependent D2 functionality was enhanced in chronically treated
Dys mutant mice, whereas it was dampened in wild-type animals.
Finally, D2S receptors are internalized and desensitized more
readily than D2L receptors65–67. Overall, the unique enhanced
functionality of presynaptic D2 receptors in the mPFC of subjects
with Dys hypofunction only after treatment with antipsychotics
adds to previous evidence showing that (1) potentiation of D2
pathways in the PFC of humans, monkeys and rodents might
facilitates executive functions50–52 and that (2) the speciﬁc genetic
deletion of presynaptic D2 receptors results in cognitive deﬁcits
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Fig. 7 Altering the D2S/D2L ratio in favor of D2S improves executive
functions exclusively in mice with genetic reduction of dysbindin-1. a Dys
+/−D2L+/− double mutant mice (magenta bar), single Dys+/− (blue
bar), single D2L+/− (red bar) and wild-type (white bar) littermates were
generated by mating double heterozygous males with naive C57 female
mice. b D2S/D2L ratio was increased in the mPFC of D2L single mutant
(Dys+/+D2L+/−) and Dys+/−D2L+/− double mutant mice compared
to wild-type controls (n= 6–10 each group; one-way ANOVA, F(3, 29)=
10.44, p < 0.0005). c Dys+/-D2L+/- double mutant mice needed less
trials to solve the EDS compared to Dys+/− mice (unpaired t-test, t= 3.13,
df= 13, p < 0.05 n= 8–12 each group. One-way ANOVA, F(3, 33)= 2.30, p
= 0.09). d Dys+/-D2L+/- double mutant mice completed the EDS in less
time compared to Dys+/− single mutant mice and wild-type controls
(one-way ANOVA, F(3, 36)= 3.64, p < 0.05; n= 8–12 each group). Error
bars represent S.E.M. *p < 0.05, **p < 0.005
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and deﬁcits of LTD expression68, essential for spatial memory
consolidation, novel spatial learning, and behavioral ﬂexibility.
Thus, presynaptic D2 could be a key element to consider in the
long-term effects of antipsychotic treatments and could provide
insights into the failure of antipsychotics to ameliorate cognitive
deﬁcits in a large part of the population.
In conclusion, by translating our ﬁndings from humans to mice
and back again, we provide evidence for a biologically supported
approach to antipsychotic treatment response. This might open
new avenues in the application of genetics to psychiatric disorders
in order to optimize the efﬁcacy of current available drugs and
develop new ones by dissecting subpopulations of responders and
non-responders based on concrete mechanistic insights.
Methods
Animals. All procedures were approved by the Italian Ministry of Health (permits
n. 230/2009-B and 107/2015-PR) and local Animal Use Committee and were
conducted in accordance with the Guide for the Care and Use of Laboratory
Animals of the National Institutes of Health and the European Community
Council Directives. Three to 6-month-old male Dys heterozygous mutant mice1
(Dys+/−) and their wild-type littermates (Dys+/+) were used. Distinct cohorts of
naive mice were used for each experiment. Dys × D2L double mutant mice were
generated by intercrossing Dys+/− with D2L+/− single mutant mice2. Mating
schemes adopted the used of C57BL6J females mice with Dys+/− or Dys+/− ×
D2L+/− double heterozygous males for the two different colonies, respectively.
Two-chamber operon ID/ED task. Attentional set-shifting was tested in the two-
chamber ID/ED Operon task as3. After random selection of the mice for the ID/ED
task, all the behavioral manipulations were obtained blind to the genotype and
pharmacological treatments of the animals. “Stuck-in-Set” ID/ED Paradigm. For
habituation to the apparatus, in the ﬁrst 2 days, mice were habituated for 45 min to
the apparatus with only neutral stimuli (Habituation 1) and trained to move from
one chamber to the other (Habituation 2). Any nose poke into the nose-poke holes
resulted in a pellet delivery into the food receptacle. The next day, mice were
trained to perform two randomly presented simple discriminations (e.g., between
smooth vs. sand cardboard; light on vs. light off; peach vs. sage) so that they were
familiar with the stimulus dimensions (Habituation 3). These exemplars were not
used again. The mice had to reach a criterion of eight correct choices out of ten
consecutive trials to complete this and each following testing stage. Performance
was measured in all phases of all experiments using number of trials to reach the
criterion; time (in minutes) to reach the criterion; time (in seconds) from breaking
the photobeams adjacent to the automated door to a nose-poke response (latency
to respond). To conduct the test, we used a stuck-in-set perseveration paradigm3,4.
This procedure is only possible when three dimensions can be manipulated. A
session started when a mouse was placed in one of the two chambers where all the
stimuli were neutral. Then the transparent door was dropped to give the mouse
access to the other chamber where the stimuli cues were on. The series of stages
comprised a simple discrimination (SD), compound dis- crimination (CD), com-
pound discrimination reversal (CDRe), IDS, IDS reversal (IDSRe), a second IDS 2
(IDS2), IDS reversal 2 (IDS2Re), EDS, and EDS reversal (EDSRe). The mice were
exposed to the tasks in this order so that they could develop a set, or bias, toward
discriminating between the correct and incorrect nose- poke hole.
Drugs. Risperidone (Sigma, Dorset, UK) was dissolved in 10 µl of acetic acid, made
up to volume with physiological saline (0.9% NaCl), pH adjusted to 6 with 0.1 M
NaOH and injected in a volume of 10 ml/kg of body weight. Animals were treated
with risperidone or saline once daily for 14 consecutive days before the ID/ED
Operon task started. Then, risperidone was dosed daily 2 h prior the behavioral
task. The dose employed was selected in order to do not affect discrimination
learning in wild-type rodents5.
Mice quantitative real-time PCR. Mice samples were homogenized and total
RNA was subsequently isolated with a PureLink RNA extraction Kit (Ambion, Life
Technologies). Yield and purity was determined by absorbance at 230, 260, and
280 nm. Isolated RNA was converted to cDNA using high capacity cDNA reverse
transcription kit (Life Technologies). Quantiﬁcation of gene expression was per-
formed with a Taqman Gene Expression Assay for DNTBP1 (Mm01250289_m1,
Life Technologies), DRD2 (dopamine D2 receptor, Mm00438545_m1, Life Tech-
nologies), DRD1 receptors (dopamine D1 receptor, Mm02620146_s1, Life Tech-
nologies), SLC6A4 (solute carrier family 6 member 4, Mm00439391_m1, Life
Technologies), for GRIN1 (glutamate receptor, ionotropic, NMDA1,
Mm00433790_m, Life Technologies), for GRIN2A (glutamate receptor, ionotropic,
NMDA2A, Mm00433802_m1, Life Technologies), for GRIN2B (glutamate recep-
tor, ionotropic, NMDA2B, Mm00433820_m1, Life Technologies), for HTR2A (5-
hydroxytryptamine, serotonin, receptor 2A, Mm00555764_m1, Life Technologies),
as well as a Taqman endogenous control assay for GAPDH (Mm99999915_g1, Life
Technologies), used as a housekeeping (normalizing) gene. TaqMan assay kits
included optimized concentrations of primers and probes to detect the target gene
expression. Quantiﬁcation of gene expression of D2S and D2L forms was per-
formed with custom made primers (DR2 Short Forward primer:
5′-ACGTGCCCTTCATCGTCACCCT-3′ DR2 Short Reverse primer: 5′-CG
GGCAGCATCCTTGAGTGG-3′; DR2 Long Forward primer: 5′-
ACGTGCCCTTCATCGTCACCC-3′; DR2 Long Reverse primer: 5′- TGGGTACA
GTTGCCCTTGAGTGGT-3′; GAPDH Forward primer: 5′-AGGTCGGTGT-
GAACGGATTTG-3′ Reverse primer: 5′-TGTAGACCATGTAGTTGAGGTCA-
3′). Total volume reaction was 25 μl using SyBr Green Master Mix reagent (Applied
Biosystems); 1–5 μl of cDNA were used as template for the reaction, with 10 μM
forward and reverse primers. Both targets and GAPDH ampliﬁcations were per-
formed in duplicate. Thermal cycling conditions included 40 cycles of 95 °C for 5
min, 95 °C for 10 s, 60 °C for 45 s. The levels of mRNA expression of these genes
were measured by real-time quantitative RT-PCR using an ABI Prism
7900 sequence detection system with 384-well format (Applied Biosystems).
Relative gene expression was quantiﬁed with the ΔΔCt Comparative method.
Stereotaxic viral injection. A lentiviral vector (Lv pPGK-eGFP-miR-D2, 108 TU/
mL, ICM—Plateforme de Vectorologie, Paris), coexpressing under the drive of the
ubiquitous PGK promoter the eGFP and a miR, speciﬁcally directed against the
mRNA of D2 (LV-miR-D2)6, was used to downregulate D2 receptors in the mPFC.
Mice were infused bilaterally (0.4 μL/each site, rate 0.3 μL/min) into the mPFC, at
two different antero-posterior sites and two dorso-ventral sites according to the
Paxinos and Franklin mouse brain atlas (AP: 1.8 and 2.0; ML: ±0.3; DV: −2.4 and
−2.9 from Bregma).
In vivo microdialysis. Concentric dialysis probe, with a dialysis portion of 2.0 mm,
were prepared with AN69 ﬁbers (Hospal Dasco, Bologna, Italy)7. Mice were
anesthetized with isoﬂurane and then placed in a stereotaxic frame (Kopf Instru-
ments, Tujunga, CA) for the probe implantation. The probe was implanted into the
mPFC, according to the Paxinos and Franklin mouse brain atlas (AP: ±1.9; ML:
±0.1; DV: −3.0 from Bregma). Microdialysis sessions started 24 h after the surgical
procedures. Probes were perfused with ringer’s solution (147.0 mM NaCl, 2.2 mM
CaCl2 and 4.0 mM KCl) at a constant ﬂow rate of 1 µl/min. Collection of basal
dialysate samples (20 µl) started 30 min after. After 60 min of basal sampling, a
solution of Quinpirole 25 nM (Sigma, Dorset, UK) was administered through the
probe for another hour of sampling collection. Dialysate samples (20 µl) were
injected into an HPLC equipped with a reverse phase column (C8 3.5 µm, Waters,
Mildford, MA, USA) and dopamine was quantiﬁed by a coulometric detector (ESA,
Coulochem II, Bedford, MA). At the end of the experiment, mice were anesthetized
with isoﬂurane and euthanized. Brains were removed and mPFC serial coronal
sections were prepared with a vibratome to identify the location of the probes. All
measurements were performed blind to the treatment and the genotype of the
animals.
Human subjects. The study protocol for healthy controls and patients with
schizophrenia was approved by the local ethics committee of the IRCCS Fonda-
zione Santa Lucia of Roma. The study on patients with ﬁrst episode of psychosis
was approved by the Ethics Committee of the Children Hospital Bambino Gesù of
Roma. All participants provided written informed assent and their parents/legal
guardians, written informed consent. Three-hundred and fourteen healthy adults
and 259 outpatients with schizophrenia who met DSM-IV-TR criteria (using to the
Structured Clinical Interview for mental disorders, SCID-I/P) were recruited and
assessed at the Santa Lucia Foundation in Rome. Forty-ﬁve ﬁrst-episode psychosis
patients with schizophrenia who met DSM-IV-TR criteria were recruited and
assessed at the Bambino Gesù Hospital in Rome (see Supplementary Tables 1 and 2
for genotypic/demographic data). To reduce the possibility of environmental
variables, only individuals born and educated in Italy and of Caucasian ethnicity
were included. Healthy individuals were screened for a current or lifetime history
of DSM-IV-TR Axis I and II disorders using the SCID-I/NP and SCID-II; they
were also interviewed to conﬁrm that no ﬁrst-degree relatives had a history of any
major psychiatric (e.g., mood disorders, schizophrenia spectrum disorders, sub-
stance abuse or dependence) or neurological disorders; and they had normal or
corrected to normal vision. In patients under 18 years old, mental disorders were
assessed using the schedule for affective disorders and Schizophrenia for school
aged children present and lifetime version (K-SADS-PL). To implement the spe-
ciﬁcity of the ﬁrst-episode psychosis diagnosis, positive, negative, disorganization,
and general symptoms were assessed with the Structured Interview for Psychosis-
Risk Syndromes (SIPS). Alcohol and drug use using sections J and L of the
Composite International Diagnostic Interview (CIDI). Functioning was rated
globally on the Childhood Global Assessment Scale (CGAS) and differentially on
the Global Functioning: Social (GF:Social) and the Global Functioning: Role (GF:
Role) scales. All patients were screened for autism-spectrum disorder using the
autism quotient child or adolescent Baron-Cohen versions. In the case of positive
screening, patients were assessed by a trained clinician on the autism diagnostic
observation schedule-generic. No participants met criteria for autism-spectrum
disorder. Demographic and clinical details included age, sex, age of illness onset,
illness duration, medical history including alcohol and drug use, admission and
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medication history. Antipsychotics dosage was converted to milligram equivalents
of Chlorpromazine. The cognitive performance in the Wisconsin Card Sorting
Test, a widely-used measure of prefrontal cognitive function that is sensitive to a
subject’s ability to generate hypotheses, establish response sets, and ﬂuently shift
sets, was separately performed by trained neuropsychologists at the IRCCS Santa
Lucia Foundation or Bambino Gesù for patients with long-term schizophrenia or
after ﬁrst-episode of psychosis, respectively.
After the neuropsychological task, DNA was extracted and puriﬁed from whole
peripheral blood using QIAamp DNA Blood Mini Kit (Quiagen). We speciﬁcally
selected a DTNBP1 haplotype composed by the three-marker single nucleotide
polymorphisms (SNPs) rs2619538, rs3213207, and rs1047631 or here, the ‘Dys
haplotype’8. DNA samples were submitted to genetic analysis for the SNPs on a
ABI7900 real-time PCR instrument (Applied Biosystems) using Custom Taqman
SNP Genotyping Assays for rs2619538 (C___3114517_10, Applied Biosystems), for
rs3213207 (C__32386418_10, Applied Biosystems), rs1047631 (C___7460562_10,
Applied Biosystems). For genotyping the manufacturer’s suggested protocol was
used. For PCR ampliﬁcation and allelic discrimination, the ABI Prism 7900
HT Sequence Detection System and SDS software version 2.1 (Applied Biosystems)
were used. HWE test and haplotype phase were performed using the software
PLINK9 for Windows http://pngu.mgh.harvard.edu/purcell/plink/. Heterozygous
subjects for all the three markers (7% of our sample) were assigned to the
Dys Hap+/− as the probability to be in this group, calculated on the haplotype
frequency of the population, was higher than 65–70%. All polymorphisms were in
HWH (p > 0.05; assessed by online resource http://www.tufts.edu/~mcourt01/
Documents/Court%20lab%20%20HW%20calculator.xls; for genotype frequencies,
see Supplementary Table 2).
CATIE study setting and design. The Clinical Antipsychotic Trials of Interven-
tion Effectiveness (CATIE, ClinicalTrials.gov Identiﬁer: NCT00014001) study was
initiated by the NIMH to compare the effectiveness of antipsychotic drugs10. The
protocol was made available to the public for comment, and a committee of sci-
entiﬁc experts, health care administrators, and consumer advocates critiqued the
study under the auspices of the NIMH. The study was conducted between January
2001 and December 2004 at 57 clinical sites in the United States. Patients were
initially randomly assigned to receive olanzapine, perphenazine, quetiapine, or
risperidone under double-blind conditions and followed for up to 18 months or
until treatment was discontinued for any reason (phase 1). The present report is
limited to phase 1 results. Eligible patients were 18 to 65 years of age; had received
a diagnosis of schizophrenia, as determined on the basis of the Structured Clinical
Interview of the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV).
Patients were excluded if they had received a diagnosis of schizoaffective disorder,
mental retardation, or other cognitive disorders; had a history of serious adverse
reactions to the proposed treatments; had only one schizophrenic episode; had a
history of treatment resistance, deﬁned by the persistence of severe symptoms
despite adequate trials of one of the proposed treatments or prior treatment with
clozapine; were pregnant or breast-feeding; or had a serious and unstable medical
condition. (Detailed information about interventions are available here11). In this
study, we included data only from patients tested from baseline to 18 months, with
genotype data available.
Human postmortem RNA sequencing and quantitative real-time PCR. For
expression of DTNBP1 we used RNAseq data from a total of 594 DLPFC from
human postmortem brain tissue (for brain quality and demographic characteristics
see12). For expression of D2L and D2S we used quantitative real-time PCR data
from a total of 375 DLPFC from human postmortem brain tissue of subjects > 16
years old (for brain quality and demographic characteristics see13). Expression
levels of mRNA were measured using an ABI Prizm 7900 sequence detection
system with 384-well format (Applied Biosystems, Foster City, CA, USA) using
Taqman assays- by-design and custom-made assays designed using PRIMER
EXPRESS software (D2S Hs_01014210_m1, Applied Biosystems; D2L Forward
primer: 3′-TGCACCGTTATCA TGAAGTCTAATG-5′, Reverse primer:
3′-CGGGCAGCCTCCACTCT-5′, Probe: 3′-AGTTTCCCAGTGAACAGG-5′).
The PCR data were acquired from the Sequence Detector Software (SDS version
2.0, Applied Biosystems) and quantiﬁed by a standard curve method. Expression
data were normalized to a geometric mean of three housekeeping genes13. The
healthy controls had no known history of psychiatric illness or substance abuse or
dependence and were screened for drug intoxication at time of death. Postmortem
toxicology screening was performed by the medical examiner on every sample to
test for illicit drug use. Prescription drug use at time of death, including anti-
psychotic (APD) and antidepressant medications, was also measured in post-
mortem blood and/or cerebellar tissue to determine which prescribed medications
were being used at the time of death. Positive results for antipsychotics were seen in
101 (out of 159) patients with schizophrenia. More details about RNA extraction,
RNA-seq preprocessing, real-time PCR, expression quantiﬁcation, and data pro-
cessing can be found here13,14.
Statistics. For animal experiments no statistical methods were used to pre-
determine sample sizes, although sample sizes were consistent with those from
previous studies3,15. No explicit randomization method was used to allocate
animals to experimental groups and mice were tested and data processed by an
investigator blind to animal treatment identity. Statistical analyses were performed
using commercial software (STATISTICA-StaSoft, 12). Results are expressed as
mean ± standard error of the mean (S.E.M.) throughout. For analysis of variance in
mice behavioral task we used ANOVA to examine the number of trials necessary to
reach the criteria, time needed to complete each stage and the latency to respond.
One-way ANOVAs for each single genotype were also performed to evaluate the
variance of performance within each group through the different stages. Moreover,
as in previous studies16 planned comparisons were performed to test the source of
signiﬁcant interactions in the different stages. For human data, a one-way ANOVA
was carried out to examine demographic variables, mRNA expression data, the
number of perseverative and non-perseverative errors and the number of categories
passed on the WCST across genotypes (Dys Hap −/−, +/− and +/+). Post hoc
analyses were conducted using Newman–Keuls test with multiple comparisons
corrections, when statistical signiﬁcance emerged in the main effects or interac-
tions. The accepted value for signiﬁcance was p < 0.05. Result sheets of statistical
tests from Stasoft detailing (wherever applicable) estimates of variance within each
group, conﬁdence intervals, effectiveness of pairing, comparison of variances across
groups, are available upon request.
Data availability. The data that support the current study are available from the
corresponding author upon reasonable request.
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